Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation). NICE technology appraisal guidance 1163
National Institute for Health and Care Excellence (NICE)
Record ID 32018015755
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1163
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1163
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Antineoplastic Agents, Immunological
- Antineoplastic Combined Chemotherapy Protocols
- BCG Vaccine
- Interleukin-15
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.